|
Post by peppy on Jan 6, 2016 15:20:17 GMT -5
And what potential patient who is in his right mind would set out on a lifetime commitment to a product sold by a totally dysfunctional company? Patients that have fantastic results are excellent reps. Even I have an old dusty resume. I like the prospects MNKD has now that SNY isn't trying to bleed us to death. Stock Options, mileage and a protected territory.
hehe screencast.com/t/qYcPIgsF5
added: screencast.com/t/lX79Njajp
|
|
|
Post by nylefty on Jan 6, 2016 15:22:36 GMT -5
...... Other than Desisto, who in his right mind would join a company with one foot in the grave?.......... And what potential patient who is in his right mind would set out on a lifetime commitment to a product sold by a totally dysfunctional company? Lifetime commitment? What are you talking about? Are you saying that once you start on Afrezza there's no turning back? There's absolutely no truth to that.
|
|
|
Post by inittowinit on Jan 6, 2016 15:34:40 GMT -5
I'm not stopping the poster. I simply asked a question.
|
|
|
Post by harryx1 on Jan 6, 2016 15:47:38 GMT -5
I'd join MannKind in a heartbeat. In fact, I think I may dust off and forward my resume to MannKind's new CEO. I'd work for free for stock options. Me too! ^^^^
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 15:56:08 GMT -5
I'm not stopping the poster. I simply asked a question. Do you think that anyone knows what to do in this situation? Everyone of us has been and is wrong and the guy is bringing up his concern and your response is just sell.
|
|
|
Post by joeypotsandpans on Jan 6, 2016 16:23:27 GMT -5
Right now, the SNY reps have been told to not hump Afrezza. I don't think MNKD has another partner lined up quite yet. The SNY contract was dated Aug 2014 and it took six months for the launch to take off. This is normal pacing of business in the pharma business. Can it be expedited? Yes of course. But not that much. I see a lull in marketing activities for the first 6 months of 2016. No forward progress. Keep in mind, MNKD does not have the resources in place to service the market. If they were to start hiring today, It will take 6 months for the troops to start performing. Other than Desisto, who in his right mind would join a company with one foot in the grave? If MannKind signs an agreement with an established pharma company "today," why would it take 6 months for that pharma's troops to start performing? MannKind doesn't need to hire anybody -- it just needs to make a deal with another company that will put some effort into marketing Afrezza. If I were a frustrated SNY rep that knew a company that has its chit together was coming on board or bought Afrezza outright...I would definitely be strapping the life preserver on and leave the sinking french freighter, especially knowing that I was mislead and betrayed by top mgmt. The reps know the product and positive feedback from both physicians and patients and with the proper backing help it reach its full potential. Why re-invent the education wheel when you have troops already trained and educated? Not sure what's in the reps employment contracts regarding definitions with respect to non compete clauses but if I felt duped and played by the company for almost a year "trying to reach unobtainable goals" with a spattering of magazine ads and a few token "educational dinners" I would have no qualms leaving. They already have entry into the existing practices on board, smooth transition especially with an attractive player. I have to be able to trust the company I work for and they (SNY) definitely would have lost mine along with their credibility. The company seems to be in complete disarray at this point...I thought that myself when they did that charade about their new divisions strategy going forward....total dog and pony show IMO.
|
|
|
Post by blindhog1 on Jan 6, 2016 17:09:55 GMT -5
If MannKind signs an agreement with an established pharma company "today," why would it take 6 months for that pharma's troops to start performing? MannKind doesn't need to hire anybody -- it just needs to make a deal with another company that will put some effort into marketing Afrezza. If I were a frustrated SNY rep that knew a company that has its chit together was coming on board or bought Afrezza outright...I would definitely be strapping the life preserver on and leave the sinking french freighter, especially knowing that I was mislead and betrayed by top mgmt. The reps know the product and positive feedback from both physicians and patients and with the proper backing help it reach its full potential. Why re-invent the education wheel when you have troops already trained and educated? Not sure what's in the reps employment contracts regarding definitions with respect to non compete clauses but if I felt duped and played by the company for almost a year "trying to reach unobtainable goals" with a spattering of magazine ads and a few token "educational dinners" I would have no qualms leaving. They already have entry into the existing practices on board, smooth transition especially with an attractive player. I have to be able to trust the company I work for and they (SNY) definitely would have lost mine along with their credibility. The company seems to be in complete disarray at this point...I thought that myself when they did that charade about their new divisions strategy going forward....total dog and pony show IMO. I like the way you think. Down around my neck of the woods we call that "Nut Cuttin' Time".
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 17:34:56 GMT -5
If MannKind signs an agreement with an established pharma company "today," why would it take 6 months for that pharma's troops to start performing? MannKind doesn't need to hire anybody -- it just needs to make a deal with another company that will put some effort into marketing Afrezza. If I were a frustrated SNY rep that knew a company that has its chit together was coming on board or bought Afrezza outright...I would definitely be strapping the life preserver on and leave the sinking french freighter, especially knowing that I was mislead and betrayed by top mgmt. The reps know the product and positive feedback from both physicians and patients and with the proper backing help it reach its full potential. Why re-invent the education wheel when you have troops already trained and educated? Not sure what's in the reps employment contracts regarding definitions with respect to non compete clauses but if I felt duped and played by the company for almost a year "trying to reach unobtainable goals" with a spattering of magazine ads and a few token "educational dinners" I would have no qualms leaving. They already have entry into the existing practices on board, smooth transition especially with an attractive player. I have to be able to trust the company I work for and they (SNY) definitely would have lost mine along with their credibility. The company seems to be in complete disarray at this point...I thought that myself when they did that charade about their new divisions strategy going forward....total dog and pony show IMO. So your SNY rep source is saying none of them had any clue this way coming? There wasn't even a whisper?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 17:45:08 GMT -5
If I were a frustrated SNY rep that knew a company that has its chit together was coming on board or bought Afrezza outright...I would definitely be strapping the life preserver on and leave the sinking french freighter, especially knowing that I was mislead and betrayed by top mgmt. The reps know the product and positive feedback from both physicians and patients and with the proper backing help it reach its full potential. Why re-invent the education wheel when you have troops already trained and educated? Not sure what's in the reps employment contracts regarding definitions with respect to non compete clauses but if I felt duped and played by the company for almost a year "trying to reach unobtainable goals" with a spattering of magazine ads and a few token "educational dinners" I would have no qualms leaving. They already have entry into the existing practices on board, smooth transition especially with an attractive player. I have to be able to trust the company I work for and they (SNY) definitely would have lost mine along with their credibility. The company seems to be in complete disarray at this point...I thought that myself when they did that charade about their new divisions strategy going forward....total dog and pony show IMO. So your SNY rep source is saying none of them had any clue this way coming? There wasn't even a whisper? usually such decisions are with held at executive level and their buddies in wall st..
|
|
|
Post by bill on Jan 6, 2016 17:57:05 GMT -5
If MannKind signs an agreement with an established pharma company "today," why would it take 6 months for that pharma's troops to start performing? MannKind doesn't need to hire anybody -- it just needs to make a deal with another company that will put some effort into marketing Afrezza. Like all drugs, Afrezza is a technical sell. SNY started to train their troops 1.5 months before launch. It would take some time for the new marketing department to get all their ducks lined up. New graphics, brochures and such. They have to figure out the compensation plan. Just to write, review and sign the contract will take a month. It's always complicated. Since we've entered the 21st century, why would MNKD go the route of expensive drug reps to detail Afrezza. There are lots of Internet based marketing choices available that are orders of magnitude less expensive, faster, and probably more effective than sales reps. Since the sales reps approach didn't work with SNY why would one try to repeat that failed experiment?
|
|
|
Post by bioexec25 on Jan 6, 2016 18:06:37 GMT -5
Like all drugs, Afrezza is a technical sell. SNY started to train their troops 1.5 months before launch. It would take some time for the new marketing department to get all their ducks lined up. New graphics, brochures and such. They have to figure out the compensation plan. Just to write, review and sign the contract will take a month. It's always complicated. Since we've entered the 21st century, why would MNKD go the route of expensive drug reps to detail Afrezza. There are lots of Internet based marketing choices available that are orders of magnitude less expensive, faster, and probably more effective than sales reps. Since the sales reps approach didn't work with SNY why would one try to repeat that failed experiment? Pharma already has huge legacy sales infrastructure and some are busy outsourcing some of it. There are several companies such as InVentiv who are able to get programs up and running faster and far more efficiently than trying to establish a whole comm ops structure internally. Many claim to be able to handle technical sales, albeit of course this is all relative. But with the right materials from a technical team and some central support it can work. It's not a panacea as outsourcing never is. But like any tool or weapon there are times and places where this makes sense given a particular situation. I'm not touting InVentiv at all in fact there probably are more suitable ones for Mnkd. I haven't done that research, just wanted to bring up the model for general consideration. Have a hardened process, ready to go may make a ton of sense. Some bio-pharma chose to hire a small team internally to drive and govern the outsourced process. www.outsourcing-pharma.com/Commercial-Services/Merck-signs-sales-outsourcing-deal
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 18:21:29 GMT -5
So your SNY rep source is saying none of them had any clue this way coming? There wasn't even a whisper? usually such decisions are with held at executive level and their buddies in wall st.. Yea of course it is a small circle of people. I just wanted him to stop speak candidly and tell us yes or no they were blind sided
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 18:31:36 GMT -5
usually such decisions are with held at executive level and their buddies in wall st.. Yea of course it is a small circle of people. I just wanted him to stop speak candidly and tell us yes or no they were blind sided no one would do that in this litigation world
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 18:32:37 GMT -5
Yea of course it is a small circle of people. I just wanted him to stop speak candidly and tell us yes or no they were blind sided no one would do that in this litigation world I meant Joey. Sorry for not being clear. I thought he had a sny source
|
|
|
Post by iclaudius on Jan 7, 2016 0:20:29 GMT -5
Here are the facts. 1. The data shows the drug is non inferior when put thru the same fda mandated process and procedure as subq's with respect to administration. 2. When the drug is administered in its designed non fda mandated manner the data reflects an unprecedented capacity to both combat chronic areas of diabetes far more effectively then past and existing medications, while increasing adherence to insulin treatment in what many have reffered to as a needle phobic socioty. Furthermore, it distinguishes itself as a more versatile and corrective treatment that allows some diabetics to enjoy less restrictive diets for the first time and thus lead a more "normal" life. 3. Exhubra, though less effective, showed positive results in its phase 1 pediatric trial, prior to being pulled. Though analysts schooled in our pharmacutical culture may imply that finding a new partner will be unlikely, I believe what separates winners from losers in any business is the recognition of value in distorted landscapes. The key is finding ways not to play by their rules. Pfizer failed Sanofi failed. I would not rule a partner like google out as a source of funding though would probably require a reorginaziton of the company. Private equity is another place I would look to next along with some foriegn pharma companies both public and private as potential suitors/partners. Lastly, look for certain established places such as cleaveland clinic to step up. This is not as binary a situation as it was or as they would have you believe. Your "2." is not a fact. It is a hypothesis based upon anecdotal data. To confirm your hypothesis would require a trial, very likely a large and long trial that could cost hundreds of millions of dollars, and MNKD would still be at risk of failing to show a significant improvement. Who would be willing to put up funds for that under those and the other current circumstances? Sanofi's dismissal of afrezza effectively put a curse on the drug, not only making it less likely to attract investors, but less likely to attract patients and doctors as well.
|
|